Core Viewpoint - Tianyi Medical has experienced a decline in stock price, with a 5.05% drop on September 19, 2023, and a cumulative decline of 4.3% over three consecutive days [1] Company Overview - Tianyi Medical, established on March 12, 1998, is located in Ningbo, Zhejiang Province, and was listed on April 7, 2022. The company specializes in the research, production, and sales of medical devices, particularly in blood purification and ward care [1] - The revenue composition of Tianyi Medical is as follows: blood purification accounts for 59.05%, ward care for 34.08%, and other products for 6.87% [1] Shareholder Information - Among the top ten circulating shareholders, Penghua Fund's Penghua Hongjia Mixed A (003165) holds 498,700 shares, unchanged from the previous period, representing 2.72% of circulating shares. The estimated floating loss today is approximately 1.12 million yuan, with a cumulative floating loss of 997,400 yuan over the three-day decline [2] - Penghua Hongjia Mixed A has a total scale of 450 million yuan and has achieved a year-to-date return of 34.51%, ranking 2279 out of 8172 in its category [2] Fund Manager Performance - The fund manager of Penghua Hongjia Mixed A is Tang Zhiyuan, who has been in the position for 8 years and 69 days. The fund's total asset scale is 1.378 billion yuan, with the best return during his tenure being 177.74% and the worst being -3.8% [3][5] Fund Holdings - Penghua Anjin One-Year Holding Period Mixed A (017083) is another fund under Penghua Fund that has a significant holding in Tianyi Medical, with 66,400 shares, accounting for 1.57% of the fund's net value. The estimated floating loss today is about 149,400 yuan, with a cumulative floating loss of 132,800 yuan over the three-day decline [4] - This fund was established on March 14, 2023, with a total scale of 125 million yuan, achieving a year-to-date return of 12.25%, ranking 5434 out of 8172 in its category [4]

国泰海通证券股份有限公司 关于宁波天益医疗器械股份有限公司 2025年半年度持续督导跟踪报告 | 保荐机构名称：国泰海通证券股份有限公司 | 被保荐公司简称：天益医疗 | | --- | --- | | 保荐代表人姓名：沈一冲 | 联系电话：021-38677509 | | 保荐代表人姓名：栾俊 | 联系电话：021-38676666 | —、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0次 | | 2.督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限 于防止关联方占用公司资源的制度、募集资金管理 | 是 | | 制度、内控制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月查询 | | （2）公司募集资金项目进展是否与信息披露文件一 致 | 是 | | 4.公司治理督导情况 ...

Core Viewpoint - Tianyi Medical announced that its actual controller and major shareholder, Mr. Wu Bin, has released and re-pledged 4.5 million shares of the company, indicating a significant movement in shareholding structure and potential liquidity needs [1] Summary by Relevant Categories Shareholding Changes - Mr. Wu Bin released 4.5 million shares from pledge, which accounts for 37.50% of his total holdings and 7.63% of the company's total share capital [1] - The same number of shares, 4.5 million, has been re-pledged, maintaining the same percentage of his holdings and the company's total share capital [1] Pledge Details - The pledge initiation date is set for September 8, 2025, with a maturity date of September 3, 2030 [1] - The pledgee is CITIC Bank Co., Ltd. Ningbo Branch, and the purpose of the pledge is for personal funding needs [1]

证券代码： 301097 证券简称：天益医疗 公告编号：2025-048 宁波天益医疗器械股份有限公司 关于公司股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宁波天益医疗器械股份有限公司（以下简称"公司"）于近日接到公司实际 控制人、持股5%以上股东吴斌先生的通知，其将所持本公司股份办理了解除质押 及质押业务，具体事项如下： 一、股东股份质押的基本情况 | | 是否为控股 | 本次解除 | 占其 | 占公 | | 是否 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股东或第一 | 质押数量 | 所持 | 司总 | 是否为限 | 为补 | 质押起 | 质押到 | 质权人 | | 名称 | 大股东及其 | （股） | 股份 | 股本 | 售股 | 充质 | 始日 | 期日 | | | | 一致行动人 | | 比例 | 比例 | | 押 | | | | | 吴斌 | 是 | 4,500,000 | 37.50 | 7.63 ...

责任编辑：小浪快报 截至6月30日，天益医疗股东户数4196.00，较上期减少0.31%；人均流通股4372股，较上期增加0.31%。 2025年1月-6月，天益医疗实现营业收入2.27亿元，同比增长11.50%；归母净利润948.32万元，同比减少 35.23%。 分红方面，天益医疗A股上市后累计派现1.02亿元。近三年，累计派现8749.78万元。 机构持仓方面，截止2025年6月30日，天益医疗十大流通股东中，鹏华弘嘉混合A（003165）位居第四 大流通股东，持股49.87万股，持股数量较上期不变。圆信永丰聚优A（010469）位居第八大流通股东， 持股28.70万股，相比上期减少2.80万股。圆信永丰医药健康A（006274）位居第十大流通股东，持股 23.00万股，相比上期减少4.55万股。鹏华优质治理混合(LOF)A（160611）退出十大流通股东之列。 9月8日，天益医疗盘中上涨2.08%，截至09:48，报45.14元/股，成交393.43万元，换手率0.48%，总市值 26.61亿元。 天益医疗今年以来股价涨25.00%，近5个交易日涨2.13%，近20日跌4.73%，近60日涨15.71 ...

证券代码：301097 证券简称：天益医疗 公告编号：2025-047 宁波天益医疗器械股份有限公司 一、对外投资概述 宁波天益医疗器械股份有限公司（以下简称"公司"或"天益医疗"）于 2025 年 2 月 14 日召开第三届董事会第二十一次会议，审议通过了《关于对外投 资的议案》，同意通过新加坡全资子公司 PRIMACRON GLOBAL PTE. LTD.（潽莱 马克隆国际有限公司，以下简称"潽莱马克隆"或"买方"）向 BELLCO S.R.L. （以下简称"卖方"）收购其 CRRT-滤器业务资产（以下简称"标的业务"）。 具体内容详见公司于 2025 年 2 月 15 日在巨潮资讯网（www.cninfo.com.cn） 披露的《关于对外投资的公告》（公告编号：2025-008）。 二、对外投资进展情况 截至本公告披露日，子公司潽莱马克隆与卖方已完成标的业务的交割工作， 卖方已将标的资产注入其为本次收购之目的于 2025 年 2 月 28 日登记设立的全资 子公司 PRIMABELL S.R.L.（意大利潽莱马贝而有限公司），并已将意大利潽莱 马贝而有限公司的 100%的股份转让给潽莱马克隆。现将相关情 ...

证券代码：301097 证券简称：天益医疗 公告编号：2025-046 宁波天益医疗器械股份有限公司 关于开立募集资金专项账户 并签署募集资金四方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宁波天益医疗器械股份有限公司（以下简称"天益医疗"或"公司"）于 2024 年 12 月 27 日召开第三届董事会第二十次会议、第三届监事会第十七次会议审议 通过了《关于变更募集资金用途的议案》，同意变更募集资金用途，同意终止原 计划由子公司宁波泰瑞斯科技有限公司实施的募投项目"综合研发中心建设项 目"，并将其剩余全部募集资金变更用于新项目"泰国生产基地建设项目"；同 时同意将剩余超募资金全部调整用于"泰国生产基地建设项目"。本次变更事项 已经公司于 2025 年 1 月 13 日召开的 2025 年第一次临时股东大会审议通过。 截至本公告披露日，公司已完成在上海浦东发展银行宁波高新区支行募集资 金专项账户的开立及募集资金四方监管协议的签署，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意宁波天益医疗器械股份有限公司首 次公开发 ...

Core Viewpoint - The National Medical Products Administration (NMPA) has announced the cancellation of medical device registration certificates for two products from two companies, indicating regulatory actions in the medical device industry [1] Company Summaries - Shenzhen Huada Yinyuan Medical Technology Co., Ltd. had its registration certificate for an automatic medical PCR analyzer (Registration No. 20233221432) revoked [1] - Ningbo Tianyi Medical Instruments Co., Ltd. had its registration certificate for a disposable titration infusion device with needle (Registration No. 20163141122) revoked [1]

Group 1 - Tianyi Medical (301097) announced that the company and its wholly-owned subsidiaries and joint ventures have not provided guarantees to any off-balance sheet entities [1] - There are no overdue external guarantees, no guarantees involved in litigation, and no losses incurred due to guarantees resulting in adverse judgments [1]

Group 1 - The company Tianyi Medical announced that as of the disclosure date, the total guarantee amount provided to its subsidiaries is approximately 489 million RMB, accounting for 41.03% of the company's latest audited consolidated net assets [1] - The actual total guarantee balance provided by the company to its subsidiaries is about 153 million RMB, which represents 12.81% of the company's latest audited consolidated net assets [1] - As of the disclosure date, the total guarantee amount provided by subsidiaries to the company is 190 million RMB, accounting for 15.94% of the company's latest audited consolidated net assets [1] Group 2 - For the first half of 2025, the revenue composition of Tianyi Medical is as follows: medical devices account for 98.81%, while other sources account for 1.19% [2] Group 3 - As of the time of reporting, the market capitalization of Tianyi Medical is 2.6 billion RMB [3]